Skip to content
10-Q

Quarterly Report

BioRestorative Therapies, Inc. BRTX

0001493152-26-023126

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 14, 2026 25.48M sh
Shares Diluted Q1 2026 · Mar 31, 2026 17.73M sh
Shares Diluted Q1 2026 · Mar 31, 2025 8.36M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$3.81M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$2.78M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $3.11M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $1.51M
Stockholders Equity Q1 2026 · Mar 31, 2026 $3.03M
Stockholders Equity Q1 2026 · Dec 31, 2025 $356.74K
Stockholders Equity Q1 2026 · Mar 31, 2025 $6.14M
Stockholders Equity Q1 2026 · Dec 31, 2024 $8.53M
Current Liabilities Q1 2026 · Mar 31, 2026 $1.61M
Current Liabilities Q1 2026 · Dec 31, 2025 $3.72M
Current Assets Q1 2026 · Mar 31, 2026 $3.8M
Current Assets Q1 2026 · Dec 31, 2025 $3.14M
Total Assets Q1 2026 · Mar 31, 2026 $4.64M
Total Assets Q1 2026 · Dec 31, 2025 $4.08M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.12
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.64
Eps Basic Q1 2026 · Mar 31, 2026 −$0.12
Eps Basic Q1 2026 · Mar 31, 2025 −$0.64
Sga Expense Q1 2026 · Mar 31, 2026 $1.48M
Sga Expense restated Q1 2026 · Mar 31, 2025 $2.18M
Rd Expense Q1 2026 · Mar 31, 2026 $1.93M
Rd Expense restated Q1 2026 · Mar 31, 2025 $2.65M
Net Income Q1 2026 · Mar 31, 2026 −$2.15M
Net Income Q1 2026 · Mar 31, 2025 −$5.34M
Operating Income Q1 2026 · Mar 31, 2026 −$3.39M
Operating Income Q1 2026 · Mar 31, 2025 −$4.81M
Gross Profit Q1 2026 · Mar 31, 2026 $15.79K
Gross Profit Q1 2026 · Mar 31, 2025 $22.09K
Cost Of Revenue Q1 2026 · Mar 31, 2026 $7.39K
Cost Of Revenue Q1 2026 · Mar 31, 2025 $2.91K
Revenue Q1 2026 · Mar 31, 2026 $23.17K
Revenue Q1 2026 · Mar 31, 2025 $25K
Capex Q1 2026 · Mar 31, 2025 $36.4K